Hormone receptor (HR) status has become an established target in treatment strategies of breast cancer. Populationbased estimates of contralateral breast cancer (CBC
A Cancer Currents blog post on a large, prospective study of breast, ovarian, and contralateral breast cancer risks associated with BRCA1 and BRCA2 gene mutations.
At 10 years after diagnosis, the risk of a primary breast cancer in the contralateral breast ranges from 3 to 10, although endocrine therapy decreases that risk. [5254 The development of a contralateral breast cancer is associated with an increased risk of distant recurrence.
After completing tamoxifen or chemotherapy, how long does risk reduction for contralateral breast cancer last?
While contralateral breast cancer is the most common malignancy among breast cancer survivors, it is still incredibly rare. The risk figure usually quoted is 0. 5 to 1. 0 per year, said senior author Courtney Vito, MD.
Contralateral breast cancer (CBC) is the most common second primary cancer in patients diagnosed with breast cancer. Patients with a history of breast cancer have an increased risk of developing a second primary breast cancer (PBC), with an annual risk of 0. 5 to 1 or a cumulative lifetime risk of 2 to 15.
A preventive procedure to remove the unaffected breast in breast cancer patients with disease in one breast may only be necessary in patients who have highrisk
A family history of breast cancer in any first or seconddegree relative was associated with an almost threefold increased risk of developing a contralateral cancer (adjusted odds ratio (OR) 2. 8, 95 confidence interval (CI) ).
How can the answer be improved?